Assistant Professor of Oncology Mayo Clinic Rochester, MN, United States
Melanoma is the fifth most commonly diagnosed cancer in the U.S. Before 2011, treatment options for individuals diagnosed with advanced melanoma were limited with a five-year overall survival rate of approximately 10%. Since 2011, significant progress has been made with FDA approval of nearly 20 treatment options resulting in a five-year overall survival rate of more than 50%. This presentation will focus on recent updates for treating advanced melanoma.
Learning Objectives:
At the conclusion of this session, participants should be able to:
Describe the role of neoadjuvant therapy in resectable clinical stage III and oligometastatic stage IV melanoma
Summarize the data regarding sequencing of immunotherapy and targeted therapy in
BRAFV600E/K mutated advanced melanoma
Explain the evolving landscape in treatment of metastatic melanoma
.jpg "Heather Montane, PA, MS, RD (she/her/hers) photo")